Abstract
Glioblastoma multiforme (GBM) is the most aggressive and prevalent variant of glioma. Temozolomide (TMZ), the treatment of first choice, is a prodrug that undergoes hydrolysis at physiological pH to form the methyldiazonic cation responsible for DNA alkylation. TMZ is the only drug available for the treatment of GBM, however, the low half-life of the drug associated with its biopharmaceut…